Do anti-epileptic drugs increase suicide in epilepsy? 10 years after the FDA alert. by Mula, M
 In 2008, the Food and Drug Administration (FDA) issued an alert about an increased 
risk of suicide ideation and behavior in people with epilepsy treated with antiepileptic drugs 
(AEDs) [1] and this was based on a meta-analysis of spontaneously reported suicidal ideation 
and behaviors from multicenter, randomized, placebo-controlled studies of 11 AEDs [2]. An 
ad hoc Task Force of the International League Against Epilepsy (ILAE) discussed the 
limitations of the FDA meta-analysis, especially the assessment of suicidality in trials not 
designed to prospectively assess suicidality [3]. Subsequently, a number of authors have tried 
to confirm or confute the FDA’s findings but most of these studies were also affected by a 
number of methodological limitations [4].  
There is no doubt that AEDs have a psychotropic potential, as they modify neuronal 
pathways that are not only relevant for seizure control, but also for mood and behavior [5]. In 
fact, some AEDs are successfully used in the treatment of mood and anxiety disorders 
[5-6]. However, AEDs may also have negative psychotropic properties and this seems to be 
more evident in epilepsy as compared to other neurological conditions where AEDs are 
frequently prescribed such as neuropathic pain, migraine or movement disorders, and this 
probably because epilepsy per se is associated with an increased prevalence of behavioral 
abnormalities [6]. For all these reasons, the issue of suicide during treatment with AEDs in 
patients with epilepsy is more complex than just a treatment-emergent adverse event. 
In the past, the FDA issued other alerts about drug-induced suicidality and everybody is 
aware of the quite controversial black-box warning about antidepressants, SSRIs in 
particular, issued in 2004. Consequences of that warning have been discussed by a number of 
authors [7-8] and, in 2007, the FDA has expanded that warning stating that depression itself 
is associated with an increased risk of suicide. However, this hasn’t happened for epilepsy 
yet, despite the increasing amount of evidence showing that epilepsy is associated with an 
increased risk of suicide.  
In the general population, suicide accounts for 1.5% of all deaths, representing the 10
th
 cause 
of death, with an incidence of 10.7/100,000 per year [103]. However, the standard mortality 
ratio for suicide in patients with epilepsy is three times higher than that of the general 
population [9]. In fact, suicide accounts for 11.5% of all deaths in epilepsy [10], with 
incidence rates of 16.9/100,000 per year [11]. Several authors have attempted to identify 
reasons for such an increased risk. Severity of the seizure disorder does not seem to play a 
role [12] and even if depression seems to be one of the most important predictors, suicide risk 
remains high even after excluding patients with a history of psychiatric disorders and 
adjusting for socioeconomic factors, suggesting that epilepsy per se is associated with an 
increased risk of suicide [13]. Some authors have suggested a link particularly with temporal 
lobe epilepsy [14] but this is not supported by other studies [15]. It is, therefore, evident that 
other, still unidentified, factors contribute to the increased risk of suicide in epilepsy.  
Someone may argue that the increased risk of suicide observed in epilepsy is given by the 
AED treatment and, for this reason, patients with epilepsy present with a higher risk as 
compared to the general population. However, epidemiological data about the bidirectional 
relationship between epilepsy and suicide clearly show that this is not the case and suggest 
the presence of other factors, probably biological and intrinsic to the pathophysiology of 
epilepsy  [16]. In addition to that, there is no doubt that psychosocial factors play also an 
important role [17]. According to the interpersonal theory of suicide, the simultaneous 
presence of thwarted belongingness (i.e. not feeling accepted by others) and perceived 
burdensomeness (i.e. the belief that one is a burden on others or society) produce the desire of 
suicide [18] and, unfortunately, it is highly possible that these two phenomena co-occur in 
people with epilepsy as this is still a highly stigmatized condition in both high- and low- 
income countries [17]. 
For a long time, suicide has been considered an unmentionable issue in epilepsy [19] but the 
FDA alert has finally forced the scientific community to face the problem. Since 2008, the 
number of publications about suicide in epilepsy has increased exponentially with 14 
publications on PubMed in 2008, 24 in 2009 and 46 in 2010. Drug companies now collect 
routinely data about suicide during regulatory trials of AEDs. Clinicians are now becoming 
aware of the problem but a lot of work still needs to be done as the majority of patients are 
still inadequately counseled about mood disorders in epilepsy and the majority of 
epileptologists are still reluctant to screen their patients for depression and even more for 
suicide. Several clinical instruments have been validated in people with epilepsy for the 
periodic screening of depression and the Neurological Depression Disorder Inventory for 
Epilepsy (NDDIE) has also been validated for suicide screening [20]. The major barrier to 
prevention of suicide in epilepsy is the lack of training in psychiatry for the majority of 
neurologists making them unease with this kind of conversation. The routine use of the 
NDDIE in the outpatient setting would facilitate clinicians in discussing about these 
problems with their patients and would stimulate the development of shared clinical 
pathways between epilepsy centers and local psychiatric services.  
In May 2013, the World Health Organization (WHO) issued the first-ever Mental Health 
Action Plan of which suicide prevention is an integral part, with the goal of reducing suicide 
rates worldwide by 10% by 2020 [21]. This is an excellent opportunity for the epilepsy 
community to gain awareness about suicide in epilepsy and for neurologists to develop 
appropriate prevention strategies in conjunction with local psychiatric services, as prevention 
is the only treatment for suicide. Over time, the management of epilepsy has become more 
and more complex requiring inputs from different health professionals. Epilepsy centers 
should offer access to different services depending on individual needs of patients, including 
specific pathways for access to mental health and prevention strategies for suicide according 
to local facilities available. In this context, an endorsement from FDA that epilepsy is 
associated with an increased risk of suicide, as it happened for depression, would probably 
stimulate physicians, at different care levels (from primary care to secondary and tertiary care 
services), to implement prevention strategies and include routine screening for depression in 
their care pathways.   
After almost 10 years, evidence favoring or contrary to the FDA alert is still lacking. Suicide 
is a complex phenomenon requiring careful attention and understanding and for this reason 
further research in epilepsy is urgently needed while ignoring, or even worse minimizing the 
problem, is totally unacceptable. 
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